IL6 and Hypoglycemia: Bezlotoxumab treatment of infected mice was able to prevent infection-mediated hypoglycemia and an increase in serum IL-6 when compared to infected PBS-treated mice (p = .0159; Supplementary Figure 2i, k), with treated, infected mice showing similar glucose and IL-6 levels to uninfected mice.